NANOPARTICLE FORMULATION CONTAINING FARNESYLTHIOSALICYLIC ACID (SALIRASIB)

It is related to farnesylthiosalicylic acid (Salirasib, FTA) loaded PLGA nanoparticles functionalized with lipid/cationic lipid-PEG (hybrid), which can cross the BBB in effective concentration. The formulations can be administered intravenously or intratumorally. La présente invention concerne des n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SÖYLEMEZOĞLU, FIGEN, OĞUZ, HATICE, KADER, KARLI, VURAL, İMRAN, KAFFASHI, ABBAS, KOŞUCU, HÜSNÜ, LÜLE, SEVDA, PEHLİVAN, SIBEL, AŞKUN, MELIKE, MUT, DEMİR, TANER, SARISÖZEN, CAN, BUĞDAYCI, EMRE
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MANUFACTURE OR TREATMENT OF NANOSTRUCTURES MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES MEDICAL OR VETERINARY SCIENCE NANOTECHNOLOGY PERFORMING OPERATIONS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES TRANSPORTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	It is related to farnesylthiosalicylic acid (Salirasib, FTA) loaded PLGA nanoparticles functionalized with lipid/cationic lipid-PEG (hybrid), which can cross the BBB in effective concentration. The formulations can be administered intravenously or intratumorally. La présente invention concerne des nanoparticules de PLGA chargées d'acide farnésylthiosalicylique (Salirasib, FTA) fonctionnalisées avec un lipide/lipide cationique-PEG (hybride) qui peuvent traverser la barrière hémato-encéphalique en une concentration efficace. Les formulations peuvent être administrées par voie intraveineuse ou par voie intratumorale.